ClinicalTrials.gg
RecruitingNCT04111692Updated Jan 26, 2026

A Prospective Observational Study of Foam Sclerotherapy .

An observational study in Autosomal Dominant Polycystic Kidney, Renal Cyst and Autosomal Dominant Polycystic Liver Disease, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Nov 2017; still recruiting 9 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic — 4 open to participants now, 7 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mayo Clinic.

Started
2017
with 1 other
Observational
9 of 15
3 open now
Registered
8th of 15
by date

Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, this one is one of 2 that started in 2017, is one of 9 observational ones, and was the 8th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

4 of the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, or all of them as a file.
02

Study summary

An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).

Read the detailed description

Cyst burden is an important determinant of outcomes in both autosomal dominant polycystic kidney disease (ADPKD) (1, 2) and autosomal dominant polycystic liver disease (ADPLD) (3, 4). Furthermore, mass symptoms (from liver and kidney volume) greatly impact upon quality of life in patients with severe disease. Cyst volume increases exponentially with age and results in the development of end-stage renal disease and hypertension, compromised quality of life due to compressive symptoms, and predisposes patients to cyst complications such as infection, hemorrhage, rupture, and torsion. Existing percutaneous treatments for cyst burden in ADPKD and ADPLD include cyst aspiration with or without sclerotherapy. Although frequently effective in the short-term, recurrence rates and the need for repeat procedures are high after these procedures (5, 6). Extrarenal disease (primarily liver disease) is the most important aspect of disease burden to ADPKD patients (7), and there are few effective treatments.

Foam sclerotherapy (FS) with 3% Sodium Tetradecyl Sulfate (STS) a sclerosing agent. (Sotradecol®; Mylan, Galway, Ireland) is approved by the FDA for the management of varicose veins. While increasing cyst burden significantly compromises quality of life, the impact of FS on patient-reported outcomes has not been evaluated. In collaboration with the Center for Science of Healthcare delivery, we have developed a patient-reported outcome tool for polycystic liver disease capable of detecting symptom burden in individuals with polycystic liver disease that has been approved by the FDA as a patient-reported outcomes tool in research. Furthermore measurement of liver and kidney volumes can be performed in the Polycystic Kidney Disease Imaging Research Core that monitors organ volumes before and after interventions. At this time, patients are interested in procedures that will alleviate and palliate their mass symptoms but desire preliminary information on the procedural efficacy. We aim to report our experience with a new therapeutic advance - FS for the treatment of liver and kidney cysts at Mayo Clinic - and to determine the impact of this procedure on patient-reported quality of life measures and changes in organ volumes.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney
  • Renal Cyst
  • Autosomal Dominant Polycystic Liver Disease
  • Hepatic Cyst

Keywords

  • hepatic cyst
  • Kidney Cyst
  • Autosomal Polycystic Liver Disease
  • Autosomal Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult subjects with ADPKD or ADPLD and large, symptomatic kidney or liver cysts followed in Nephrology or Hepatology clinics at Mayo Clinic, or de novo referrals to Mayo Clinic, Rochester, MN will be invited to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Clinical diagnosis of ADPKD or ADPLD
  • 1-3 large, non-exophytic liver or kidney cyst
  • Compressive symptoms from dominant cyst

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Absence of ADPKD or ADPLD
  • Largest cyst \<4cm in all 3 dimensions or largest cyst volume \<400cc
  • >3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)
  • Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS
  • Lacking capacity to provide to FS of liver or kidney cysts
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in Pain Inventory

    Measured using self assessed brief pain inventory (short form) questionnaire, using a scale of 0 is no pain and 10 is pain as bad as you can imagine

    Time frame: Baseline, 1 month, 6 month, 12 month

  2. Change in Self Assessed Quality of life

    Measured using the linear analogue self assessed questionnaire, using a scale of 0 is as bad as it can be and 10 is as good as it can be

    Time frame: Baseline, 1 month, 6 month, 12 month

  3. Change in health related quality of life

    Measured using the self assessed Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), using a scale that ranges from yes and no or all of the time to none of the time

    Time frame: Baseline, 1 month, 6 month, 12 month

  4. Change in Polycystic Liver Disease Quality of Life

    Measured using the self assessed Polycystic Liver Disease Questionnaire, using a scale that ranges from never/not at all to always/a lot

    Time frame: Baseline, 1 month, 6 month, 12 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Nov 2027, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
Oct 1, 2019
StartActual
Nov 6, 2017
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04111692
Lead sponsor
Mayo Clinic
Responsible party
Marie Hogan (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 1, 2019
Start date
Nov 6, 2017
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

Cassie Howe, CRC
Contact
howe.cassie@mayo.edu
507-266-1230
Marie Hogan, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion